nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—CYP2B6—Thiotepa—urinary bladder cancer	0.137	0.253	CbGbCtD
Citalopram—ABCB1—Mitomycin—urinary bladder cancer	0.0928	0.171	CbGbCtD
Citalopram—CYP3A4—Thiotepa—urinary bladder cancer	0.0422	0.0776	CbGbCtD
Citalopram—CYP2B6—Cisplatin—urinary bladder cancer	0.0379	0.0697	CbGbCtD
Citalopram—CYP2E1—Etoposide—urinary bladder cancer	0.0377	0.0694	CbGbCtD
Citalopram—ABCB1—Gemcitabine—urinary bladder cancer	0.0267	0.0492	CbGbCtD
Citalopram—CYP1A2—Fluorouracil—urinary bladder cancer	0.0261	0.0481	CbGbCtD
Citalopram—CYP2B6—Doxorubicin—urinary bladder cancer	0.0254	0.0467	CbGbCtD
Citalopram—CYP1A2—Etoposide—urinary bladder cancer	0.0218	0.0401	CbGbCtD
Citalopram—ABCB1—Cisplatin—urinary bladder cancer	0.0194	0.0357	CbGbCtD
Citalopram—ABCB1—Etoposide—urinary bladder cancer	0.0191	0.0351	CbGbCtD
Citalopram—ABCB1—Doxorubicin—urinary bladder cancer	0.013	0.0239	CbGbCtD
Citalopram—ABCB1—Methotrexate—urinary bladder cancer	0.0126	0.0232	CbGbCtD
Citalopram—CYP2D6—Doxorubicin—urinary bladder cancer	0.0123	0.0226	CbGbCtD
Citalopram—CYP3A4—Etoposide—urinary bladder cancer	0.0114	0.021	CbGbCtD
Citalopram—CYP3A4—Doxorubicin—urinary bladder cancer	0.0078	0.0143	CbGbCtD
Citalopram—CYP2C19—urine—urinary bladder cancer	0.00423	0.0957	CbGeAlD
Citalopram—CYP1A2—urine—urinary bladder cancer	0.00346	0.0782	CbGeAlD
Citalopram—CYP2E1—urine—urinary bladder cancer	0.00311	0.0703	CbGeAlD
Citalopram—CYP3A4—urine—urinary bladder cancer	0.0025	0.0566	CbGeAlD
Citalopram—CYP2D6—urine—urinary bladder cancer	0.00246	0.0557	CbGeAlD
Citalopram—CHRM1—prostate gland—urinary bladder cancer	0.00183	0.0413	CbGeAlD
Citalopram—ADRA1A—prostate gland—urinary bladder cancer	0.0015	0.0339	CbGeAlD
Citalopram—HRH1—prostate gland—urinary bladder cancer	0.00116	0.0263	CbGeAlD
Citalopram—CYP2E1—prostate gland—urinary bladder cancer	0.00112	0.0252	CbGeAlD
Citalopram—ADRA1A—epithelium—urinary bladder cancer	0.0011	0.0249	CbGeAlD
Citalopram—HTR2C—female reproductive system—urinary bladder cancer	0.00106	0.0239	CbGeAlD
Citalopram—ADRA1A—renal system—urinary bladder cancer	0.00102	0.0231	CbGeAlD
Citalopram—SLC6A4—female reproductive system—urinary bladder cancer	0.001	0.0226	CbGeAlD
Citalopram—CHRM1—female reproductive system—urinary bladder cancer	0.000997	0.0225	CbGeAlD
Citalopram—CYP2E1—seminal vesicle—urinary bladder cancer	0.000944	0.0213	CbGeAlD
Citalopram—SLC6A2—female reproductive system—urinary bladder cancer	0.000881	0.0199	CbGeAlD
Citalopram—HRH1—epithelium—urinary bladder cancer	0.000854	0.0193	CbGeAlD
Citalopram—CYP1A2—renal system—urinary bladder cancer	0.000846	0.0191	CbGeAlD
Citalopram—HRH1—smooth muscle tissue—urinary bladder cancer	0.000823	0.0186	CbGeAlD
Citalopram—CYP2B6—renal system—urinary bladder cancer	0.000811	0.0183	CbGeAlD
Citalopram—HRH1—urethra—urinary bladder cancer	0.000778	0.0176	CbGeAlD
Citalopram—CYP2E1—renal system—urinary bladder cancer	0.000761	0.0172	CbGeAlD
Citalopram—CYP2C19—vagina—urinary bladder cancer	0.00075	0.017	CbGeAlD
Citalopram—CYP2E1—urethra—urinary bladder cancer	0.000748	0.0169	CbGeAlD
Citalopram—CYP2B6—female reproductive system—urinary bladder cancer	0.000649	0.0147	CbGeAlD
Citalopram—ABCB1—prostate gland—urinary bladder cancer	0.000636	0.0144	CbGeAlD
Citalopram—HRH1—female reproductive system—urinary bladder cancer	0.000634	0.0143	CbGeAlD
Citalopram—CYP3A4—renal system—urinary bladder cancer	0.000612	0.0138	CbGeAlD
Citalopram—CYP2E1—female reproductive system—urinary bladder cancer	0.000609	0.0138	CbGeAlD
Citalopram—CYP2D6—renal system—urinary bladder cancer	0.000603	0.0136	CbGeAlD
Citalopram—CYP2B6—vagina—urinary bladder cancer	0.000587	0.0133	CbGeAlD
Citalopram—HRH1—vagina—urinary bladder cancer	0.000574	0.013	CbGeAlD
Citalopram—ABCB1—seminal vesicle—urinary bladder cancer	0.000538	0.0122	CbGeAlD
Citalopram—SLC6A2—lymph node—urinary bladder cancer	0.000516	0.0117	CbGeAlD
Citalopram—CYP3A4—female reproductive system—urinary bladder cancer	0.00049	0.0111	CbGeAlD
Citalopram—CYP2D6—female reproductive system—urinary bladder cancer	0.000483	0.0109	CbGeAlD
Citalopram—ABCB1—epithelium—urinary bladder cancer	0.000467	0.0106	CbGeAlD
Citalopram—ABCB1—renal system—urinary bladder cancer	0.000433	0.0098	CbGeAlD
Citalopram—ABCB1—urethra—urinary bladder cancer	0.000426	0.00963	CbGeAlD
Citalopram—HRH1—lymph node—urinary bladder cancer	0.000371	0.00839	CbGeAlD
Citalopram—ABCB1—female reproductive system—urinary bladder cancer	0.000347	0.00785	CbGeAlD
Citalopram—ABCB1—vagina—urinary bladder cancer	0.000314	0.0071	CbGeAlD
Citalopram—ABCB1—lymph node—urinary bladder cancer	0.000203	0.00459	CbGeAlD
Citalopram—Visual impairment—Epirubicin—urinary bladder cancer	9.05e-05	0.000282	CcSEcCtD
Citalopram—Mediastinal disorder—Methotrexate—urinary bladder cancer	9.05e-05	0.000282	CcSEcCtD
Citalopram—Agranulocytosis—Doxorubicin—urinary bladder cancer	9.03e-05	0.000282	CcSEcCtD
Citalopram—Chills—Methotrexate—urinary bladder cancer	9.01e-05	0.000281	CcSEcCtD
Citalopram—Diarrhoea—Cisplatin—urinary bladder cancer	8.89e-05	0.000277	CcSEcCtD
Citalopram—Erythema multiforme—Epirubicin—urinary bladder cancer	8.88e-05	0.000277	CcSEcCtD
Citalopram—Alopecia—Methotrexate—urinary bladder cancer	8.87e-05	0.000276	CcSEcCtD
Citalopram—Vomiting—Gemcitabine—urinary bladder cancer	8.86e-05	0.000276	CcSEcCtD
Citalopram—Bradycardia—Doxorubicin—urinary bladder cancer	8.85e-05	0.000276	CcSEcCtD
Citalopram—Mental disorder—Methotrexate—urinary bladder cancer	8.79e-05	0.000274	CcSEcCtD
Citalopram—Rash—Gemcitabine—urinary bladder cancer	8.79e-05	0.000274	CcSEcCtD
Citalopram—Dermatitis—Gemcitabine—urinary bladder cancer	8.78e-05	0.000274	CcSEcCtD
Citalopram—Eye disorder—Epirubicin—urinary bladder cancer	8.78e-05	0.000274	CcSEcCtD
Citalopram—Hypersensitivity—Etoposide—urinary bladder cancer	8.77e-05	0.000273	CcSEcCtD
Citalopram—Tinnitus—Epirubicin—urinary bladder cancer	8.76e-05	0.000273	CcSEcCtD
Citalopram—Erythema—Methotrexate—urinary bladder cancer	8.74e-05	0.000272	CcSEcCtD
Citalopram—Malnutrition—Methotrexate—urinary bladder cancer	8.74e-05	0.000272	CcSEcCtD
Citalopram—Haemoglobin—Doxorubicin—urinary bladder cancer	8.73e-05	0.000272	CcSEcCtD
Citalopram—Headache—Gemcitabine—urinary bladder cancer	8.73e-05	0.000272	CcSEcCtD
Citalopram—Flushing—Epirubicin—urinary bladder cancer	8.72e-05	0.000272	CcSEcCtD
Citalopram—Cardiac disorder—Epirubicin—urinary bladder cancer	8.72e-05	0.000272	CcSEcCtD
Citalopram—Vomiting—Fluorouracil—urinary bladder cancer	8.72e-05	0.000272	CcSEcCtD
Citalopram—Rhinitis—Doxorubicin—urinary bladder cancer	8.71e-05	0.000271	CcSEcCtD
Citalopram—Haemorrhage—Doxorubicin—urinary bladder cancer	8.69e-05	0.000271	CcSEcCtD
Citalopram—Hepatitis—Doxorubicin—urinary bladder cancer	8.69e-05	0.000271	CcSEcCtD
Citalopram—Hypoaesthesia—Doxorubicin—urinary bladder cancer	8.65e-05	0.000269	CcSEcCtD
Citalopram—Rash—Fluorouracil—urinary bladder cancer	8.64e-05	0.000269	CcSEcCtD
Citalopram—Dermatitis—Fluorouracil—urinary bladder cancer	8.63e-05	0.000269	CcSEcCtD
Citalopram—Pharyngitis—Doxorubicin—urinary bladder cancer	8.63e-05	0.000269	CcSEcCtD
Citalopram—Headache—Fluorouracil—urinary bladder cancer	8.59e-05	0.000268	CcSEcCtD
Citalopram—Urinary tract disorder—Doxorubicin—urinary bladder cancer	8.58e-05	0.000267	CcSEcCtD
Citalopram—Oedema peripheral—Doxorubicin—urinary bladder cancer	8.56e-05	0.000267	CcSEcCtD
Citalopram—Dysgeusia—Methotrexate—urinary bladder cancer	8.56e-05	0.000267	CcSEcCtD
Citalopram—Asthenia—Etoposide—urinary bladder cancer	8.54e-05	0.000266	CcSEcCtD
Citalopram—Connective tissue disorder—Doxorubicin—urinary bladder cancer	8.54e-05	0.000266	CcSEcCtD
Citalopram—Angiopathy—Epirubicin—urinary bladder cancer	8.52e-05	0.000266	CcSEcCtD
Citalopram—Urethral disorder—Doxorubicin—urinary bladder cancer	8.52e-05	0.000265	CcSEcCtD
Citalopram—Immune system disorder—Epirubicin—urinary bladder cancer	8.48e-05	0.000264	CcSEcCtD
Citalopram—Mediastinal disorder—Epirubicin—urinary bladder cancer	8.46e-05	0.000264	CcSEcCtD
Citalopram—Back pain—Methotrexate—urinary bladder cancer	8.45e-05	0.000263	CcSEcCtD
Citalopram—Chills—Epirubicin—urinary bladder cancer	8.43e-05	0.000263	CcSEcCtD
Citalopram—Pruritus—Etoposide—urinary bladder cancer	8.42e-05	0.000262	CcSEcCtD
Citalopram—Arrhythmia—Epirubicin—urinary bladder cancer	8.39e-05	0.000261	CcSEcCtD
Citalopram—Visual impairment—Doxorubicin—urinary bladder cancer	8.38e-05	0.000261	CcSEcCtD
Citalopram—Alopecia—Epirubicin—urinary bladder cancer	8.3e-05	0.000259	CcSEcCtD
Citalopram—Nausea—Gemcitabine—urinary bladder cancer	8.28e-05	0.000258	CcSEcCtD
Citalopram—Vomiting—Cisplatin—urinary bladder cancer	8.26e-05	0.000257	CcSEcCtD
Citalopram—Vision blurred—Methotrexate—urinary bladder cancer	8.23e-05	0.000257	CcSEcCtD
Citalopram—Mental disorder—Epirubicin—urinary bladder cancer	8.23e-05	0.000256	CcSEcCtD
Citalopram—Erythema multiforme—Doxorubicin—urinary bladder cancer	8.22e-05	0.000256	CcSEcCtD
Citalopram—Rash—Cisplatin—urinary bladder cancer	8.19e-05	0.000255	CcSEcCtD
Citalopram—Dermatitis—Cisplatin—urinary bladder cancer	8.19e-05	0.000255	CcSEcCtD
Citalopram—Malnutrition—Epirubicin—urinary bladder cancer	8.18e-05	0.000255	CcSEcCtD
Citalopram—Erythema—Epirubicin—urinary bladder cancer	8.18e-05	0.000255	CcSEcCtD
Citalopram—Diarrhoea—Etoposide—urinary bladder cancer	8.15e-05	0.000254	CcSEcCtD
Citalopram—Nausea—Fluorouracil—urinary bladder cancer	8.14e-05	0.000254	CcSEcCtD
Citalopram—Eye disorder—Doxorubicin—urinary bladder cancer	8.12e-05	0.000253	CcSEcCtD
Citalopram—Ill-defined disorder—Methotrexate—urinary bladder cancer	8.11e-05	0.000253	CcSEcCtD
Citalopram—Tinnitus—Doxorubicin—urinary bladder cancer	8.1e-05	0.000252	CcSEcCtD
Citalopram—Anaemia—Methotrexate—urinary bladder cancer	8.08e-05	0.000252	CcSEcCtD
Citalopram—Cardiac disorder—Doxorubicin—urinary bladder cancer	8.07e-05	0.000251	CcSEcCtD
Citalopram—Flushing—Doxorubicin—urinary bladder cancer	8.07e-05	0.000251	CcSEcCtD
Citalopram—Flatulence—Epirubicin—urinary bladder cancer	8.06e-05	0.000251	CcSEcCtD
Citalopram—Tension—Epirubicin—urinary bladder cancer	8.02e-05	0.00025	CcSEcCtD
Citalopram—Dysgeusia—Epirubicin—urinary bladder cancer	8.01e-05	0.000249	CcSEcCtD
Citalopram—Nervousness—Epirubicin—urinary bladder cancer	7.94e-05	0.000247	CcSEcCtD
Citalopram—Back pain—Epirubicin—urinary bladder cancer	7.91e-05	0.000246	CcSEcCtD
Citalopram—Angiopathy—Doxorubicin—urinary bladder cancer	7.88e-05	0.000246	CcSEcCtD
Citalopram—Malaise—Methotrexate—urinary bladder cancer	7.88e-05	0.000246	CcSEcCtD
Citalopram—Dizziness—Etoposide—urinary bladder cancer	7.87e-05	0.000245	CcSEcCtD
Citalopram—Muscle spasms—Epirubicin—urinary bladder cancer	7.86e-05	0.000245	CcSEcCtD
Citalopram—Immune system disorder—Doxorubicin—urinary bladder cancer	7.85e-05	0.000245	CcSEcCtD
Citalopram—Vertigo—Methotrexate—urinary bladder cancer	7.85e-05	0.000245	CcSEcCtD
Citalopram—Mediastinal disorder—Doxorubicin—urinary bladder cancer	7.83e-05	0.000244	CcSEcCtD
Citalopram—Leukopenia—Methotrexate—urinary bladder cancer	7.82e-05	0.000244	CcSEcCtD
Citalopram—Chills—Doxorubicin—urinary bladder cancer	7.8e-05	0.000243	CcSEcCtD
Citalopram—Arrhythmia—Doxorubicin—urinary bladder cancer	7.76e-05	0.000242	CcSEcCtD
Citalopram—Nausea—Cisplatin—urinary bladder cancer	7.72e-05	0.000241	CcSEcCtD
Citalopram—Vision blurred—Epirubicin—urinary bladder cancer	7.71e-05	0.00024	CcSEcCtD
Citalopram—Alopecia—Doxorubicin—urinary bladder cancer	7.68e-05	0.000239	CcSEcCtD
Citalopram—Cough—Methotrexate—urinary bladder cancer	7.62e-05	0.000238	CcSEcCtD
Citalopram—Mental disorder—Doxorubicin—urinary bladder cancer	7.61e-05	0.000237	CcSEcCtD
Citalopram—Ill-defined disorder—Epirubicin—urinary bladder cancer	7.59e-05	0.000236	CcSEcCtD
Citalopram—Convulsion—Methotrexate—urinary bladder cancer	7.57e-05	0.000236	CcSEcCtD
Citalopram—Vomiting—Etoposide—urinary bladder cancer	7.57e-05	0.000236	CcSEcCtD
Citalopram—Malnutrition—Doxorubicin—urinary bladder cancer	7.57e-05	0.000236	CcSEcCtD
Citalopram—Erythema—Doxorubicin—urinary bladder cancer	7.57e-05	0.000236	CcSEcCtD
Citalopram—Anaemia—Epirubicin—urinary bladder cancer	7.56e-05	0.000235	CcSEcCtD
Citalopram—Agitation—Epirubicin—urinary bladder cancer	7.51e-05	0.000234	CcSEcCtD
Citalopram—Rash—Etoposide—urinary bladder cancer	7.51e-05	0.000234	CcSEcCtD
Citalopram—Dermatitis—Etoposide—urinary bladder cancer	7.5e-05	0.000234	CcSEcCtD
Citalopram—Headache—Etoposide—urinary bladder cancer	7.46e-05	0.000232	CcSEcCtD
Citalopram—Flatulence—Doxorubicin—urinary bladder cancer	7.45e-05	0.000232	CcSEcCtD
Citalopram—Myalgia—Methotrexate—urinary bladder cancer	7.44e-05	0.000232	CcSEcCtD
Citalopram—Chest pain—Methotrexate—urinary bladder cancer	7.44e-05	0.000232	CcSEcCtD
Citalopram—Arthralgia—Methotrexate—urinary bladder cancer	7.44e-05	0.000232	CcSEcCtD
Citalopram—Tension—Doxorubicin—urinary bladder cancer	7.42e-05	0.000231	CcSEcCtD
Citalopram—Dysgeusia—Doxorubicin—urinary bladder cancer	7.41e-05	0.000231	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	7.39e-05	0.00023	CcSEcCtD
Citalopram—Malaise—Epirubicin—urinary bladder cancer	7.37e-05	0.00023	CcSEcCtD
Citalopram—Discomfort—Methotrexate—urinary bladder cancer	7.35e-05	0.000229	CcSEcCtD
Citalopram—Nervousness—Doxorubicin—urinary bladder cancer	7.35e-05	0.000229	CcSEcCtD
Citalopram—Vertigo—Epirubicin—urinary bladder cancer	7.35e-05	0.000229	CcSEcCtD
Citalopram—Syncope—Epirubicin—urinary bladder cancer	7.33e-05	0.000228	CcSEcCtD
Citalopram—Leukopenia—Epirubicin—urinary bladder cancer	7.32e-05	0.000228	CcSEcCtD
Citalopram—Back pain—Doxorubicin—urinary bladder cancer	7.32e-05	0.000228	CcSEcCtD
Citalopram—Muscle spasms—Doxorubicin—urinary bladder cancer	7.27e-05	0.000227	CcSEcCtD
Citalopram—Palpitations—Epirubicin—urinary bladder cancer	7.23e-05	0.000225	CcSEcCtD
Citalopram—Confusional state—Methotrexate—urinary bladder cancer	7.19e-05	0.000224	CcSEcCtD
Citalopram—Loss of consciousness—Epirubicin—urinary bladder cancer	7.19e-05	0.000224	CcSEcCtD
Citalopram—Cough—Epirubicin—urinary bladder cancer	7.13e-05	0.000222	CcSEcCtD
Citalopram—Anaphylactic shock—Methotrexate—urinary bladder cancer	7.13e-05	0.000222	CcSEcCtD
Citalopram—Vision blurred—Doxorubicin—urinary bladder cancer	7.13e-05	0.000222	CcSEcCtD
Citalopram—Convulsion—Epirubicin—urinary bladder cancer	7.08e-05	0.000221	CcSEcCtD
Citalopram—Infection—Methotrexate—urinary bladder cancer	7.08e-05	0.000221	CcSEcCtD
Citalopram—Nausea—Etoposide—urinary bladder cancer	7.07e-05	0.00022	CcSEcCtD
Citalopram—Hypertension—Epirubicin—urinary bladder cancer	7.06e-05	0.00022	CcSEcCtD
Citalopram—Ill-defined disorder—Doxorubicin—urinary bladder cancer	7.02e-05	0.000219	CcSEcCtD
Citalopram—Nervous system disorder—Methotrexate—urinary bladder cancer	6.99e-05	0.000218	CcSEcCtD
Citalopram—Anaemia—Doxorubicin—urinary bladder cancer	6.99e-05	0.000218	CcSEcCtD
Citalopram—Thrombocytopenia—Methotrexate—urinary bladder cancer	6.98e-05	0.000218	CcSEcCtD
Citalopram—Myalgia—Epirubicin—urinary bladder cancer	6.96e-05	0.000217	CcSEcCtD
Citalopram—Arthralgia—Epirubicin—urinary bladder cancer	6.96e-05	0.000217	CcSEcCtD
Citalopram—Chest pain—Epirubicin—urinary bladder cancer	6.96e-05	0.000217	CcSEcCtD
Citalopram—Agitation—Doxorubicin—urinary bladder cancer	6.95e-05	0.000217	CcSEcCtD
Citalopram—Anxiety—Epirubicin—urinary bladder cancer	6.94e-05	0.000216	CcSEcCtD
Citalopram—Skin disorder—Methotrexate—urinary bladder cancer	6.93e-05	0.000216	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	6.91e-05	0.000215	CcSEcCtD
Citalopram—Hyperhidrosis—Methotrexate—urinary bladder cancer	6.89e-05	0.000215	CcSEcCtD
Citalopram—Discomfort—Epirubicin—urinary bladder cancer	6.88e-05	0.000214	CcSEcCtD
Citalopram—Malaise—Doxorubicin—urinary bladder cancer	6.82e-05	0.000213	CcSEcCtD
Citalopram—Dry mouth—Epirubicin—urinary bladder cancer	6.81e-05	0.000212	CcSEcCtD
Citalopram—Vertigo—Doxorubicin—urinary bladder cancer	6.8e-05	0.000212	CcSEcCtD
Citalopram—Anorexia—Methotrexate—urinary bladder cancer	6.8e-05	0.000212	CcSEcCtD
Citalopram—Syncope—Doxorubicin—urinary bladder cancer	6.78e-05	0.000211	CcSEcCtD
Citalopram—Leukopenia—Doxorubicin—urinary bladder cancer	6.77e-05	0.000211	CcSEcCtD
Citalopram—Confusional state—Epirubicin—urinary bladder cancer	6.73e-05	0.00021	CcSEcCtD
Citalopram—Palpitations—Doxorubicin—urinary bladder cancer	6.69e-05	0.000208	CcSEcCtD
Citalopram—Oedema—Epirubicin—urinary bladder cancer	6.67e-05	0.000208	CcSEcCtD
Citalopram—Anaphylactic shock—Epirubicin—urinary bladder cancer	6.67e-05	0.000208	CcSEcCtD
Citalopram—Hypotension—Methotrexate—urinary bladder cancer	6.66e-05	0.000208	CcSEcCtD
Citalopram—Loss of consciousness—Doxorubicin—urinary bladder cancer	6.65e-05	0.000207	CcSEcCtD
Citalopram—Infection—Epirubicin—urinary bladder cancer	6.63e-05	0.000207	CcSEcCtD
Citalopram—Cough—Doxorubicin—urinary bladder cancer	6.6e-05	0.000206	CcSEcCtD
Citalopram—Shock—Epirubicin—urinary bladder cancer	6.57e-05	0.000205	CcSEcCtD
Citalopram—Convulsion—Doxorubicin—urinary bladder cancer	6.55e-05	0.000204	CcSEcCtD
Citalopram—Nervous system disorder—Epirubicin—urinary bladder cancer	6.54e-05	0.000204	CcSEcCtD
Citalopram—Thrombocytopenia—Epirubicin—urinary bladder cancer	6.53e-05	0.000204	CcSEcCtD
Citalopram—Hypertension—Doxorubicin—urinary bladder cancer	6.53e-05	0.000204	CcSEcCtD
Citalopram—Tachycardia—Epirubicin—urinary bladder cancer	6.51e-05	0.000203	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	6.5e-05	0.000202	CcSEcCtD
Citalopram—Skin disorder—Epirubicin—urinary bladder cancer	6.48e-05	0.000202	CcSEcCtD
Citalopram—Hyperhidrosis—Epirubicin—urinary bladder cancer	6.45e-05	0.000201	CcSEcCtD
Citalopram—Insomnia—Methotrexate—urinary bladder cancer	6.45e-05	0.000201	CcSEcCtD
Citalopram—Myalgia—Doxorubicin—urinary bladder cancer	6.44e-05	0.000201	CcSEcCtD
Citalopram—Arthralgia—Doxorubicin—urinary bladder cancer	6.44e-05	0.000201	CcSEcCtD
Citalopram—Chest pain—Doxorubicin—urinary bladder cancer	6.44e-05	0.000201	CcSEcCtD
Citalopram—Anxiety—Doxorubicin—urinary bladder cancer	6.42e-05	0.0002	CcSEcCtD
Citalopram—Paraesthesia—Methotrexate—urinary bladder cancer	6.4e-05	0.0002	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	6.4e-05	0.000199	CcSEcCtD
Citalopram—Discomfort—Doxorubicin—urinary bladder cancer	6.36e-05	0.000198	CcSEcCtD
Citalopram—Anorexia—Epirubicin—urinary bladder cancer	6.36e-05	0.000198	CcSEcCtD
Citalopram—Dyspnoea—Methotrexate—urinary bladder cancer	6.36e-05	0.000198	CcSEcCtD
Citalopram—Somnolence—Methotrexate—urinary bladder cancer	6.34e-05	0.000198	CcSEcCtD
Citalopram—Dry mouth—Doxorubicin—urinary bladder cancer	6.3e-05	0.000196	CcSEcCtD
Citalopram—Dyspepsia—Methotrexate—urinary bladder cancer	6.28e-05	0.000196	CcSEcCtD
Citalopram—Hypotension—Epirubicin—urinary bladder cancer	6.24e-05	0.000194	CcSEcCtD
Citalopram—Confusional state—Doxorubicin—urinary bladder cancer	6.23e-05	0.000194	CcSEcCtD
Citalopram—Decreased appetite—Methotrexate—urinary bladder cancer	6.2e-05	0.000193	CcSEcCtD
Citalopram—Anaphylactic shock—Doxorubicin—urinary bladder cancer	6.17e-05	0.000192	CcSEcCtD
Citalopram—Oedema—Doxorubicin—urinary bladder cancer	6.17e-05	0.000192	CcSEcCtD
Citalopram—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	6.16e-05	0.000192	CcSEcCtD
Citalopram—Fatigue—Methotrexate—urinary bladder cancer	6.15e-05	0.000192	CcSEcCtD
Citalopram—Infection—Doxorubicin—urinary bladder cancer	6.13e-05	0.000191	CcSEcCtD
Citalopram—Pain—Methotrexate—urinary bladder cancer	6.1e-05	0.00019	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	6.08e-05	0.000189	CcSEcCtD
Citalopram—Shock—Doxorubicin—urinary bladder cancer	6.07e-05	0.000189	CcSEcCtD
Citalopram—Nervous system disorder—Doxorubicin—urinary bladder cancer	6.06e-05	0.000189	CcSEcCtD
Citalopram—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.05e-05	0.000188	CcSEcCtD
Citalopram—Insomnia—Epirubicin—urinary bladder cancer	6.04e-05	0.000188	CcSEcCtD
Citalopram—Tachycardia—Doxorubicin—urinary bladder cancer	6.03e-05	0.000188	CcSEcCtD
Citalopram—Skin disorder—Doxorubicin—urinary bladder cancer	6e-05	0.000187	CcSEcCtD
Citalopram—Paraesthesia—Epirubicin—urinary bladder cancer	5.99e-05	0.000187	CcSEcCtD
Citalopram—Hyperhidrosis—Doxorubicin—urinary bladder cancer	5.97e-05	0.000186	CcSEcCtD
Citalopram—Dyspnoea—Epirubicin—urinary bladder cancer	5.95e-05	0.000185	CcSEcCtD
Citalopram—Somnolence—Epirubicin—urinary bladder cancer	5.93e-05	0.000185	CcSEcCtD
Citalopram—Anorexia—Doxorubicin—urinary bladder cancer	5.89e-05	0.000183	CcSEcCtD
Citalopram—Feeling abnormal—Methotrexate—urinary bladder cancer	5.88e-05	0.000183	CcSEcCtD
Citalopram—Dyspepsia—Epirubicin—urinary bladder cancer	5.87e-05	0.000183	CcSEcCtD
Citalopram—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5.83e-05	0.000182	CcSEcCtD
Citalopram—Decreased appetite—Epirubicin—urinary bladder cancer	5.8e-05	0.000181	CcSEcCtD
Citalopram—Hypotension—Doxorubicin—urinary bladder cancer	5.77e-05	0.00018	CcSEcCtD
Citalopram—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	5.76e-05	0.00018	CcSEcCtD
Citalopram—Fatigue—Epirubicin—urinary bladder cancer	5.75e-05	0.000179	CcSEcCtD
Citalopram—Constipation—Epirubicin—urinary bladder cancer	5.71e-05	0.000178	CcSEcCtD
Citalopram—Pain—Epirubicin—urinary bladder cancer	5.71e-05	0.000178	CcSEcCtD
Citalopram—Urticaria—Methotrexate—urinary bladder cancer	5.66e-05	0.000177	CcSEcCtD
Citalopram—Abdominal pain—Methotrexate—urinary bladder cancer	5.64e-05	0.000176	CcSEcCtD
Citalopram—Body temperature increased—Methotrexate—urinary bladder cancer	5.64e-05	0.000176	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.63e-05	0.000175	CcSEcCtD
Citalopram—Insomnia—Doxorubicin—urinary bladder cancer	5.58e-05	0.000174	CcSEcCtD
Citalopram—Paraesthesia—Doxorubicin—urinary bladder cancer	5.54e-05	0.000173	CcSEcCtD
Citalopram—Dyspnoea—Doxorubicin—urinary bladder cancer	5.5e-05	0.000172	CcSEcCtD
Citalopram—Feeling abnormal—Epirubicin—urinary bladder cancer	5.5e-05	0.000171	CcSEcCtD
Citalopram—Somnolence—Doxorubicin—urinary bladder cancer	5.49e-05	0.000171	CcSEcCtD
Citalopram—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.46e-05	0.00017	CcSEcCtD
Citalopram—Dyspepsia—Doxorubicin—urinary bladder cancer	5.44e-05	0.000169	CcSEcCtD
Citalopram—Decreased appetite—Doxorubicin—urinary bladder cancer	5.37e-05	0.000167	CcSEcCtD
Citalopram—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	5.33e-05	0.000166	CcSEcCtD
Citalopram—Fatigue—Doxorubicin—urinary bladder cancer	5.32e-05	0.000166	CcSEcCtD
Citalopram—Urticaria—Epirubicin—urinary bladder cancer	5.3e-05	0.000165	CcSEcCtD
Citalopram—Pain—Doxorubicin—urinary bladder cancer	5.28e-05	0.000165	CcSEcCtD
Citalopram—Constipation—Doxorubicin—urinary bladder cancer	5.28e-05	0.000165	CcSEcCtD
Citalopram—Abdominal pain—Epirubicin—urinary bladder cancer	5.28e-05	0.000164	CcSEcCtD
Citalopram—Body temperature increased—Epirubicin—urinary bladder cancer	5.28e-05	0.000164	CcSEcCtD
Citalopram—Hypersensitivity—Methotrexate—urinary bladder cancer	5.25e-05	0.000164	CcSEcCtD
Citalopram—Asthenia—Methotrexate—urinary bladder cancer	5.12e-05	0.000159	CcSEcCtD
Citalopram—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.09e-05	0.000159	CcSEcCtD
Citalopram—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.05e-05	0.000157	CcSEcCtD
Citalopram—Pruritus—Methotrexate—urinary bladder cancer	5.04e-05	0.000157	CcSEcCtD
Citalopram—Hypersensitivity—Epirubicin—urinary bladder cancer	4.92e-05	0.000153	CcSEcCtD
Citalopram—Urticaria—Doxorubicin—urinary bladder cancer	4.91e-05	0.000153	CcSEcCtD
Citalopram—Body temperature increased—Doxorubicin—urinary bladder cancer	4.88e-05	0.000152	CcSEcCtD
Citalopram—Abdominal pain—Doxorubicin—urinary bladder cancer	4.88e-05	0.000152	CcSEcCtD
Citalopram—Diarrhoea—Methotrexate—urinary bladder cancer	4.88e-05	0.000152	CcSEcCtD
Citalopram—Asthenia—Epirubicin—urinary bladder cancer	4.79e-05	0.000149	CcSEcCtD
Citalopram—Pruritus—Epirubicin—urinary bladder cancer	4.72e-05	0.000147	CcSEcCtD
Citalopram—Dizziness—Methotrexate—urinary bladder cancer	4.72e-05	0.000147	CcSEcCtD
Citalopram—Diarrhoea—Epirubicin—urinary bladder cancer	4.57e-05	0.000142	CcSEcCtD
Citalopram—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.55e-05	0.000142	CcSEcCtD
Citalopram—Vomiting—Methotrexate—urinary bladder cancer	4.53e-05	0.000141	CcSEcCtD
Citalopram—Rash—Methotrexate—urinary bladder cancer	4.5e-05	0.00014	CcSEcCtD
Citalopram—Dermatitis—Methotrexate—urinary bladder cancer	4.49e-05	0.00014	CcSEcCtD
Citalopram—Headache—Methotrexate—urinary bladder cancer	4.47e-05	0.000139	CcSEcCtD
Citalopram—Asthenia—Doxorubicin—urinary bladder cancer	4.43e-05	0.000138	CcSEcCtD
Citalopram—Dizziness—Epirubicin—urinary bladder cancer	4.41e-05	0.000137	CcSEcCtD
Citalopram—Pruritus—Doxorubicin—urinary bladder cancer	4.37e-05	0.000136	CcSEcCtD
Citalopram—Vomiting—Epirubicin—urinary bladder cancer	4.24e-05	0.000132	CcSEcCtD
Citalopram—Nausea—Methotrexate—urinary bladder cancer	4.24e-05	0.000132	CcSEcCtD
Citalopram—Diarrhoea—Doxorubicin—urinary bladder cancer	4.22e-05	0.000132	CcSEcCtD
Citalopram—Rash—Epirubicin—urinary bladder cancer	4.21e-05	0.000131	CcSEcCtD
Citalopram—Dermatitis—Epirubicin—urinary bladder cancer	4.2e-05	0.000131	CcSEcCtD
Citalopram—Headache—Epirubicin—urinary bladder cancer	4.18e-05	0.00013	CcSEcCtD
Citalopram—Dizziness—Doxorubicin—urinary bladder cancer	4.08e-05	0.000127	CcSEcCtD
Citalopram—Nausea—Epirubicin—urinary bladder cancer	3.96e-05	0.000124	CcSEcCtD
Citalopram—Vomiting—Doxorubicin—urinary bladder cancer	3.93e-05	0.000122	CcSEcCtD
Citalopram—Rash—Doxorubicin—urinary bladder cancer	3.89e-05	0.000121	CcSEcCtD
Citalopram—Dermatitis—Doxorubicin—urinary bladder cancer	3.89e-05	0.000121	CcSEcCtD
Citalopram—Headache—Doxorubicin—urinary bladder cancer	3.87e-05	0.000121	CcSEcCtD
Citalopram—Nausea—Doxorubicin—urinary bladder cancer	3.67e-05	0.000114	CcSEcCtD
Citalopram—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.94e-05	0.000212	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—NQO1—urinary bladder cancer	1.94e-05	0.000212	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.91e-05	0.000209	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—NQO1—urinary bladder cancer	1.9e-05	0.000208	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.89e-05	0.000207	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.88e-05	0.000206	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—S100B—urinary bladder cancer	1.86e-05	0.000204	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.82e-05	0.000199	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.82e-05	0.000199	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.8e-05	0.000198	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.8e-05	0.000197	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.77e-05	0.000194	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.77e-05	0.000194	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.77e-05	0.000194	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—RHOA—urinary bladder cancer	1.77e-05	0.000193	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.76e-05	0.000193	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.73e-05	0.00019	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.72e-05	0.000188	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.71e-05	0.000187	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.69e-05	0.000185	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.68e-05	0.000184	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NCOR1—urinary bladder cancer	1.68e-05	0.000183	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.67e-05	0.000183	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.67e-05	0.000183	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—RHOA—urinary bladder cancer	1.65e-05	0.000181	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—IL2—urinary bladder cancer	1.63e-05	0.000179	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.62e-05	0.000177	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	1.62e-05	0.000177	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—S100B—urinary bladder cancer	1.61e-05	0.000177	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—S100B—urinary bladder cancer	1.61e-05	0.000176	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.61e-05	0.000176	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—S100B—urinary bladder cancer	1.58e-05	0.000173	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	1.58e-05	0.000173	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—CXCL8—urinary bladder cancer	1.55e-05	0.00017	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—RHOA—urinary bladder cancer	1.53e-05	0.000168	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.53e-05	0.000167	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—RHOA—urinary bladder cancer	1.53e-05	0.000167	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.51e-05	0.000165	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—RHOA—urinary bladder cancer	1.5e-05	0.000164	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—TYMS—urinary bladder cancer	1.5e-05	0.000164	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	1.48e-05	0.000163	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	1.48e-05	0.000163	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—IL2—urinary bladder cancer	1.48e-05	0.000162	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.48e-05	0.000162	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TERT—urinary bladder cancer	1.48e-05	0.000162	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.47e-05	0.000162	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—TYMS—urinary bladder cancer	1.47e-05	0.000161	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.46e-05	0.00016	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	1.45e-05	0.000159	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	1.45e-05	0.000159	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.45e-05	0.000159	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NCOR1—urinary bladder cancer	1.45e-05	0.000159	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NCOR1—urinary bladder cancer	1.45e-05	0.000158	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.43e-05	0.000156	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NCOR1—urinary bladder cancer	1.42e-05	0.000156	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—GPX1—urinary bladder cancer	1.42e-05	0.000156	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.42e-05	0.000155	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.41e-05	0.000155	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.41e-05	0.000155	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—IL2—urinary bladder cancer	1.41e-05	0.000155	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—IL2—urinary bladder cancer	1.41e-05	0.000154	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.41e-05	0.000154	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	1.4e-05	0.000153	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—GPX1—urinary bladder cancer	1.39e-05	0.000152	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—IL2—urinary bladder cancer	1.39e-05	0.000152	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.37e-05	0.00015	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	1.37e-05	0.00015	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.37e-05	0.00015	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—FGFR3—urinary bladder cancer	1.36e-05	0.000148	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.35e-05	0.000148	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.35e-05	0.000147	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.34e-05	0.000147	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.34e-05	0.000147	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—CXCL8—urinary bladder cancer	1.32e-05	0.000144	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ESR1—urinary bladder cancer	1.32e-05	0.000144	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	1.31e-05	0.000144	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	1.28e-05	0.000141	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL2—urinary bladder cancer	1.28e-05	0.000141	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL2—urinary bladder cancer	1.28e-05	0.00014	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TERT—urinary bladder cancer	1.28e-05	0.00014	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TERT—urinary bladder cancer	1.28e-05	0.00014	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL2—urinary bladder cancer	1.26e-05	0.000138	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TERT—urinary bladder cancer	1.26e-05	0.000137	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.24e-05	0.000136	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.22e-05	0.000134	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.19e-05	0.00013	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.18e-05	0.000129	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.18e-05	0.000129	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—FGFR3—urinary bladder cancer	1.17e-05	0.000129	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—FGFR3—urinary bladder cancer	1.17e-05	0.000128	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CREBBP—urinary bladder cancer	1.15e-05	0.000126	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—FGFR3—urinary bladder cancer	1.15e-05	0.000126	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ESR1—urinary bladder cancer	1.14e-05	0.000125	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.14e-05	0.000125	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IGF1—urinary bladder cancer	1.14e-05	0.000125	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ESR1—urinary bladder cancer	1.14e-05	0.000124	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.13e-05	0.000124	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—EGFR—urinary bladder cancer	1.13e-05	0.000124	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.12e-05	0.000123	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.12e-05	0.000123	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.12e-05	0.000123	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ESR1—urinary bladder cancer	1.12e-05	0.000123	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.11e-05	0.000121	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.11e-05	0.000121	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.09e-05	0.00012	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.09e-05	0.00012	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.09e-05	0.00012	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.09e-05	0.00012	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.07e-05	0.000118	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	1.07e-05	0.000117	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.06e-05	0.000116	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.06e-05	0.000116	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.05e-05	0.000115	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.05e-05	0.000115	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.04e-05	0.000114	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	1.04e-05	0.000114	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PPARG—urinary bladder cancer	1.04e-05	0.000114	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.03e-05	0.000113	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.03e-05	0.000113	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.03e-05	0.000113	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	1.02e-05	0.000112	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	1e-05	0.00011	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	9.99e-06	0.000109	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CREBBP—urinary bladder cancer	9.96e-06	0.000109	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	9.91e-06	0.000109	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GPX1—urinary bladder cancer	9.88e-06	0.000108	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	9.87e-06	0.000108	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IGF1—urinary bladder cancer	9.84e-06	0.000108	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	9.82e-06	0.000108	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	9.81e-06	0.000107	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—EGFR—urinary bladder cancer	9.79e-06	0.000107	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	9.7e-06	0.000106	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	9.69e-06	0.000106	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—MTHFR—urinary bladder cancer	9.67e-06	0.000106	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	9.66e-06	0.000106	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.65e-06	0.000106	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	9.64e-06	0.000106	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	9.51e-06	0.000104	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	9.28e-06	0.000102	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—KRAS—urinary bladder cancer	9.25e-06	0.000101	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.2e-06	0.000101	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	9.16e-06	0.0001	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	9.12e-06	9.98e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	9.1e-06	9.97e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	9.1e-06	9.97e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	9.04e-06	9.9e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—RHOA—urinary bladder cancer	9.01e-06	9.87e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	8.87e-06	9.72e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—TYMS—urinary bladder cancer	8.84e-06	9.68e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.8e-06	9.63e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	8.75e-06	9.59e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	8.74e-06	9.57e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	8.74e-06	9.57e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	8.53e-06	9.35e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	8.37e-06	9.17e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GPX1—urinary bladder cancer	8.37e-06	9.16e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	8.37e-06	9.16e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	8.34e-06	9.14e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	8.29e-06	9.07e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	8.26e-06	9.04e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	8.24e-06	9.02e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	8.22e-06	9e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	8.21e-06	8.99e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	8.2e-06	8.97e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PPARG—urinary bladder cancer	8.04e-06	8.8e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	7.94e-06	8.69e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	7.91e-06	8.66e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	7.89e-06	8.64e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	7.86e-06	8.61e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	7.86e-06	8.6e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PPARG—urinary bladder cancer	7.84e-06	8.59e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	7.79e-06	8.53e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	7.74e-06	8.47e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	7.72e-06	8.46e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	7.72e-06	8.45e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	7.64e-06	8.36e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL2—urinary bladder cancer	7.59e-06	8.31e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	7.56e-06	8.28e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CREBBP—urinary bladder cancer	7.54e-06	8.25e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	7.44e-06	8.15e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	7.4e-06	8.1e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PPARG—urinary bladder cancer	7.39e-06	8.09e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	7.37e-06	8.07e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	7.34e-06	8.04e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTEN—urinary bladder cancer	7.3e-06	7.99e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	7.26e-06	7.95e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	7.18e-06	7.86e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	7.16e-06	7.84e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	7.15e-06	7.83e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTEN—urinary bladder cancer	7.15e-06	7.83e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	7.14e-06	7.82e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	7.13e-06	7.81e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	7.11e-06	7.79e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	7.1e-06	7.78e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	7.05e-06	7.71e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	7.02e-06	7.69e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	7e-06	7.67e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—EP300—urinary bladder cancer	6.96e-06	7.62e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	6.85e-06	7.5e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.82e-06	7.47e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—EP300—urinary bladder cancer	6.82e-06	7.46e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EP300—urinary bladder cancer	6.81e-06	7.45e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	6.79e-06	7.43e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.74e-06	7.38e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.74e-06	7.38e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	6.7e-06	7.33e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	6.68e-06	7.31e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SRC—urinary bladder cancer	6.62e-06	7.25e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	6.6e-06	7.22e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	6.5e-06	7.11e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.46e-06	7.07e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.34e-06	6.94e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	6.33e-06	6.93e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	6.32e-06	6.92e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PPARG—urinary bladder cancer	6.26e-06	6.86e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.17e-06	6.76e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	6.02e-06	6.59e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.96e-06	6.53e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MYC—urinary bladder cancer	5.93e-06	6.5e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	5.91e-06	6.47e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	5.82e-06	6.37e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	5.82e-06	6.37e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	5.8e-06	6.35e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	5.78e-06	6.33e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	5.69e-06	6.23e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	5.62e-06	6.16e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTEN—urinary bladder cancer	5.51e-06	6.04e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	5.48e-06	6e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	5.46e-06	5.98e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.38e-06	5.89e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	5.38e-06	5.89e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	5.38e-06	5.89e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—EP300—urinary bladder cancer	5.26e-06	5.76e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—EP300—urinary bladder cancer	5.13e-06	5.62e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTEN—urinary bladder cancer	5.07e-06	5.55e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.93e-06	5.39e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—urinary bladder cancer	4.87e-06	5.33e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	4.86e-06	5.32e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.84e-06	5.3e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.83e-06	5.29e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	4.78e-06	5.23e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	4.66e-06	5.1e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	4.64e-06	5.08e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.64e-06	5.08e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	4.57e-06	5.01e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTEN—urinary bladder cancer	4.3e-06	4.7e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—EP300—urinary bladder cancer	4.1e-06	4.49e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.8e-06	4.16e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.32e-06	3.63e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.16e-06	3.46e-05	CbGpPWpGaD
